G
Gwenaelle Gravis
Researcher at French Institute of Health and Medical Research
Publications - 253
Citations - 12641
Gwenaelle Gravis is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: Prostate cancer & Medicine. The author has an hindex of 45, co-authored 190 publications receiving 9811 citations. Previous affiliations of Gwenaelle Gravis include Centre national de la recherche scientifique & Aix-Marseille University.
Papers
More filters
Journal ArticleDOI
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
Johann S. de Bono,Stéphane Oudard,Mustafa Ozguroglu,Steinbjørn Hansen,Jean-Pascal Machiels,Ivo Kocák,Gwenaelle Gravis,Istvan Bodrogi,Mary J. MacKenzie,Liji Shen,Martin Roessner,Sunil Gupta,A. Oliver Sartor +12 more
TL;DR: Treatment with cabazitaxel plus prednisone has important clinical antitumour activity, improving overall survival in patients with metastatic castration-resistant prostate cancer whose disease has progressed during or after docetaxel-based therapy.
Journal ArticleDOI
Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial.
Thomas Powles,Ignacio Duran,Michiel S. van der Heijden,Yohann Loriot,Nicholas J. Vogelzang,Ugo De Giorgi,Stéphane Oudard,Margitta Retz,Daniel Castellano,Aristotelis Bamias,Aude Flechon,Gwenaelle Gravis,Syed A. Hussain,Toshimi Takano,Ning Leng,Edward E. Kadel,Romain Banchereau,Priti S. Hegde,Sanjeev Mariathasan,Na Cui,Xiaodong Shen,Christina Louise Derleth,Marjorie C. Green,Alain Ravaud +23 more
TL;DR: Atezolizumab was not associated with significantly longer overall survival than chemotherapy in patients with platinum-refractory metastatic urothelial carcinoma overexpressing PD-L1, thus precluding further formal statistical analysis.
Journal ArticleDOI
Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial
Gwenaelle Gravis,Karim Fizazi,Florence Joly,Stéphane Oudard,Franck Priou,Benjamin Esterni,Igor Latorzeff,Remy Delva,Ivan Krakowski,Brigitte Laguerre,Frederic Rolland,Christine Theodore,Gael Deplanque,Jean Marc Ferrero,Damien Pouessel,Loic Mourey,Philippe Beuzeboc,Sylvie Zanetta,Muriel Habibian,Jean-François Berdah,Jérôme Dauba,Marjorie Baciuchka,Christian Platini,Claude Linassier,Jean Luc Labourey,Jean-Pascal Machiels,Claude El Kouri,Alain Ravaud,Etienne Suc,Jean-Christophe Eymard,Ali Hasbini,Guilhem Bousquet,Michel Soulié +32 more
TL;DR: Docetaxel should not be used as part of first-line treatment for patients with non-castrate metastatic prostate cancer, and the data monitoring committee recommended treatment with granulocyte colony-stimulating factor.
Journal ArticleDOI
Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer
Tomasz M. Beer,Eugene D. Kwon,Charles G. Drake,Karim Fizazi,Christopher J. Logothetis,Gwenaelle Gravis,Vinod Ganju,Jonathan Polikoff,Fred Saad,Piotr Humanski,Josep M. Piulats,Pablo González Mella,Siobhan Ng,Dirk Jaeger,Francis Parnis,Fabio Franke,J. Puente,Roman Carvajal,Lisa Sengeløv,M. Brent McHenry,Arvind Varma,Alfonsus J. M. van den Eertwegh,Winald R. Gerritsen +22 more
TL;DR: Ipilimumab did not improve OS in patients with metastatic castration-resistant prostate cancer and the observed increases in progression-free survival and prostate-specific antigen response rates suggest antitumor activity in a patient subset.
Journal ArticleDOI
Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial.
Thomas Powles,Mark M. Kockx,Alejo Rodriguez-Vida,Ignacio Duran,Simon J. Crabb,Michiel S. van der Heijden,Bernadett Szabados,Albert Font Pous,Gwenaelle Gravis,Urbano Anido Herranz,Andrew Protheroe,Alain Ravaud,Denis Maillet,Maria Jose Mendez,Cristina Suarez,Mark Linch,Aaron Prendergast,Peter A. van Dam,Diana Stanoeva,Sofie Daelemans,Sanjeev Mariathasan,Joy S. Tea,Kelly Mousa,Romain Banchereau,Daniel Castellano +24 more
TL;DR: A single-arm multicenter phase 2 trial demonstrates clinical efficacy of neoadjuvant PD-L1 blockade in patients with resectable muscle-invasive bladder cancer ineligible for cisplatin and examines biomarkers associated with patient outcome.